Genmab value drops by over USD 1.5bn after royalties defeat

After a ruling against Genmab encompassing two different royalty issues with partner Janssen, the market value of the firm has dropped by DKK 10.8bn (USD 1.58bn).
Photo: Tuala Hjarnø / Genmab / PR
Photo: Tuala Hjarnø / Genmab / PR
by marketwire, translated by catherine brett

Since trading opened on Friday, Genmab’s market value has dropped by DKK 10.8bn (USD 1.58bn), as news broke that arbitrators had ruled in Janssen’s favor in a royalties dispute between the two firms.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading